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Background: In Zimbabwe, while the Xpert MTB/RIF assay is being used for diagnosing tuberculosis and
rifampicin-resistance, re-treatment tuberculosis (TB) patients are still expected to have culture and drug sensi-
tivity testing (CDST) performed at national reference laboratories for conﬁrmation. The study aim was to docu-
ment the Xpert MTB/RIF assay scale-up and assess how the CDST system functioned for re-treatment TB
patients.
Methods: We performed an ecologic study using national aggregate data.
Results: Use of the Xpert MTB/RIF assay increased from 11 829 to 68 153 between 2012 and 2016. Xpert
assays worked well, with successful tests in more than 90% of cases, TB detection rates at 15–17% and rifam-
picin resistance in <10%. During Xpert scale-up, the number of sputum specimens from re-treatment TB
patients reaching national reference laboratories for CDST increased from 12% to 51%. In terms of laboratory
performance, culture contamination increased from 3% to 17%, positive cultures from 13% to 17% and suc-
cessful CDST from 6% to 14%: the proportion of CDST showing any resistance to rifampicin averaged 44%.
From 2009 to 2016, the proportion of notiﬁed re-treatment TB patients with successful CDST increased from
<1% to 7%.
Conclusions: While components of Zimbabwe’s CDST system for re-treatment TB patients showed some
changes during the scale-up of the Xpert MTB/RIF assay, overall performance was poor. The country must
either invest in improving CDST performance or in advanced molecular diagnostic technology.
Keywords: culture and drug sensitivity testing, Mycobacterium tuberculosis, re-treatment tuberculosis, rifampicin resistance, Xpert
MTB/RIF, Zimbabwe
Introduction
Recurrent or re-treatment tuberculosis (TB) is a global public
health challenge. It is an important risk factor for drug-resistant
TB, especially multidrug-resistant TB (MDR-TB; deﬁned as TB
that does not respond to at least isoniazid and rifampicin, the
two most powerful anti-TB drugs).1 Treating MDR-TB is more dif-
ﬁcult and more expensive than drug-susceptible TB, with a
regimen that is usually 24 months long and associated with
numerous adverse drug events.2 While the overall TB burden is
declining in Zimbabwe, the proportion of re-treatment TB
patients remained at around 11% (n=5691) between 2015 and
2016, and treatment outcomes among these patients have
tended to be worse than those observed in new TB cases.1,3
One of the reasons for worse treatment outcomes could be
due to failure to detect drug resistance. It is thus essential that
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re-treatment TB patients are appropriately investigated through
mycobacterial culture and drug susceptibility testing (CDST), the
gold standard for TB diagnostic conﬁrmation and drug suscepti-
bility testing of anti-TB drugs. Global and national TB guidelines
recommend that sputum specimens for every re-treatment TB
patient should be sent to a reference laboratory to identify drug
resistance and MDR-TB.4,5 In Zimbabwe, CDST is provided by the
two national reference laboratories (NRLs): the National TB
Reference Laboratory in Bulawayo and the National Microbiology
Reference Laboratory in Harare, which serve the southern and
northern regions, respectively. The process of getting sputum
specimens from peripheral health facilities to the NRLs is not
only difﬁcult, but also inconsistent and unreliable.3 These chal-
lenges have been reported in both African and Asian coun-
tries.6–9
One of the major advances in the diagnosis of TB in the last
7 y has been the introduction, deployment and scale-up of the
Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA). This is a
highly sensitive, fully automated and commercially available
nucleic acid ampliﬁcation test for use with sputum and other
body specimens.10 The Xpert MTB/RIF assay requires minimal
expertise and has a short sample processing time of 2 h to con-
ﬁrm Mycobacterium tuberculosis (MTB) and to detect rifampicin
resistance. However, this test is also more expensive and has
infrastructure and technical issues related to deployment in per-
ipheral settings.11,12 Initially, the World Health Organization
(WHO) recommended use of Xpert MTB/RIF assay for those sus-
pected of having MDR-TB and for those with presumptive TB
who are also co-infected with human immunodeﬁciency virus
(HIV).13 However, in 2013 the WHO made a conditional recom-
mendation that the Xpert MTB/RIF assay be considered as the
initial diagnostic test for all people requiring investigation for
TB.14
In late 2011, the Xpert MTB/RIF assay was scaled up
throughout Zimbabwe. High-risk groups such as HIV-infected
persons with presumptive TB, those with a previous history of TB
treatment, miners and prisoners were initially prioritised for
Xpert MTB/RIF investigation. However, since 2014 the country
has adopted the WHO recommendations and the Xpert MTB/RIF
assay is now the initial diagnostic test for all presumptive TB
patients. While those diagnosed with TB by the Xpert MTB/RIF
assay are started on treatment, national guidelines still recom-
mend that all notiﬁed re-treatment TB patients and those with
rifampicin resistance also have sputum specimens sent to the
NRLs for CDST to conﬁrm the Xpert MTB/RIF results and to detect
resistance to other drugs, especially isoniazid.5
Given the national recommendations and the scale-up of the
Xpert MTB/RIF technology in Zimbabwe, it is highly likely that
the number of sputum specimens being sent to and received by
the NRLs has increased. During this time, the human resources
in the NRLs did not change. We hypothesised that the increased
workload may have led to a deterioration in CDST performance.
There is no published information in Zimbabwe either before or
during the scale-up of the Xpert MTB/RIF assay about the pro-
portion of re-treatment TB cases that have sputum specimens
sent to the NRLs or how well the NRLs have performed with
respect to CDST.
The aim of this study was to assess how the Zimbabwe myco-
bacterial CDST system for re-treatment TB patients has
functioned during the scale-up of the Xpert MTB/RIF assay.
Speciﬁc objectives were to document and assess for the whole
country the scale-up and performance of the Xpert MTB/RIF assay
between 2011 and 2016 and, before and during the scale-up of
the Xpert MTB/RIF assay, the number and proportion of notiﬁed
re-treatment TB patients who had sputum specimens received by
the NRLs along with the performance and results of CDST.
Methods
Study design
This was an ecologic study involving secondary analyses of
aggregate data routinely collected by the national TB control
programme.
Setting
General
Zimbabwe is a landlocked country situated in southern Africa
that is bordered by high HIV- and TB-prevalent countries: South
Africa, Botswana, Mozambique and Zambia. The country’s popu-
lation is approximately 13 million according to the last census
and it has a gross domestic product (GDP) of $924 per capita,
compared with $1589 per capita for the sub-Saharan Africa
region.15,16 Zimbabwe is divided into northern and southern
regions, made up of ﬁve administrative provinces in each region,
with a total of 62 administrative districts.
TB is a major public health threat, with the prevalence of dis-
ease (all forms) estimated at 275 per 100 000 population (95%
conﬁdence interval [CI] 217 to 334 per 100 000) according to
the 2014 TB prevalence survey for Zimbabwe.5 TB treatment
services are offered in all public health facilities, where they are
integrated with other general health services. The laboratory
network consists of at least one TB diagnosing centre per district
(translating to 1.4 smear microscopy centres per 100 000 popu-
lation) and two NRLs that conduct CDST, each NRL serving one
region. Both NRLs provide culturing of MTB as well as phenotypic
and molecular drug sensitivity testing (DST). Molecular tests
such as the Hain’s line probe assay (LPA) were introduced at the
two NRLs in 2015/2016 and are used to complement but not
replace phenotypic DST.
Management of CDST in re-treatment patients
Re-treatment TB patients are those who previously received at
least 1 month or more of anti-TB drugs and are diagnosed once
again with TB. They include relapses, treatment after failure and
treatment after loss to follow-up on a ﬁrst-line treatment regi-
men.17 All patients diagnosed with re-treatment TB are sup-
posed to be investigated by the Xpert MTB/RIF assay and are
also supposed to submit an additional sputum specimen to one
of the two NRLs for CDST, as part of government policy. Once
rifampicin resistance is detected, patients are initiated on a
standardised treatment regimen pending CDST results. The spu-
tum specimens are collected at peripheral sites and transported
through government and non-governmental organization part-
ners to the NRLs. At the NRLs, all samples are decontaminated
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using sodium hydroxide to kill commensal bacteria, which may
contaminate the cultures. The resultant sputum pellet is inocu-
lated on both Lowenstein–Jensen (LJ) agar media and
Mycobacteria Growth Indicator Tube (MGIT) 960 liquid media
(Becton Dickinson, Franklin Lakes, NJ, USA) before being incu-
bated for growth. All pure growths of MTB (with no contami-
nants) are subcultured and DSTs are carried out on both LJ and
MGIT 960 media using the proportion method.18,19 The perfor-
mances of both NRLs as measured by the results from an exter-
nal quality assurance programme have hitherto been excellent.
Study population
The study included aggregate data on the number of Xpert
MTB/RIF instruments deployed in Zimbabwe between 2011 and
2016 along with their performance and assay results and the
number of patients notiﬁed with re-treatment TB in Zimbabwe
between 2008 and 2016. The pre-Xpert era included the years
2008–2010 and the Xpert era included the years 2011–2016.
Data variables, sources of data and data collection
The following data variables were collected. For the scale-up of
the Xpert MTB/RIF assay, data included year, instruments
deployed each year, assays done each year, unsuccessful tests
(errors reported by the instrument), successful tests in which
valid Xpert assay results were produced, tests showing MTB and
tests showing rifampicin-resistant TB (RR-TB). The source of data
was the National Laboratory Annual Report for Tuberculosis. For
notiﬁed patients with re-treatment TB, data included year, re-
treatment TB patients registered nationally each year, sputum
specimens received at the NRLs, culture contamination, MTB
culture growth, CDST performed and results of CDST in terms of
resistance to isoniazid and/or rifampicin. The sources of data
were the WHO Global TB Reports (for Zimbabwe), the
Laboratory Information Management System for each NRL and
physical records (laboratory request forms for CDST) for each
NRL. Data collection was carried out in August 2017 using a
paper-based questionnaire.
Analysis and statistics
Data were double-entered from the paper-based questionnaire
into EpiData (version 4.0.1.44 for data entry and version
2.2.2.186 for data analysis [EpiData Association, Odense,
Denmark]). Numbers and proportions were reported for all
numeric and categorical variables, and bar graphs were plotted
to show annual trends for the relevant variables. The χ2 test
was used to compare differences in categorical variables
between the pre-Xpert and Xpert periods. Levels of signiﬁcance
were set at 5%.
Ethics
Ethics approval for this study was obtained from the Medical
Research Council of Zimbabwe as well as the Ethics Advisory
Group, International Union Against Tuberculosis and Lung
Disease (The Union), Paris, France.
Results
Scale-up of the Xpert MTB/RIF assay in Zimbabwe
The number of Xpert MTB/RIF instruments deployed each year in
Zimbabwe between 2011 and 2016 is shown in Figure 1. There
was a large increase in the number of instruments in 2013 and
from 2015 onwards. The number of Xpert MTB/RIF assays per-
formed along with the results for each year between 2012 and
2016 are shown in Table 1. There were no data available for 2011.
Between 2012 and 2016 there was a steady increase in the abso-
lute number of tests performed, along with those tests detecting
MTB and RR-TB. For the years 2012–2013 and 2015–2016, there
were fairly similar results showing successful tests at greater than
90%, the proportion detecting MTB ranging from 15% to 17% and
the proportion with RR-TB at less than 10%. In 2014, there was a
large increase in errors, a reduction in successful tests and in the
detection of MTB and an increase in RR-TB.
Re-treatment TB and receipt of sputum specimens
at NRLs
The annual number of notiﬁcations of re-treatment TB along
with the number (and proportions) of sputum specimens from
each patient received at the NRLs in the pre-Xpert era and the
Xpert era are shown in Figure 2. The proportions of patients for
whom sputum specimens were received at the NRLs remained
fairly constant, at around 11–13% in the pre-Xpert era, but
increased exponentially from 16% to 51% in the Xpert era.
During the Xpert era, 28.2% of sputum specimens from re-
treatment TB patients were received at the NRLs, which was sig-
niﬁcantly higher than the 12.1% that were received during the
pre-Xpert era (p<0.001).
Performance of CDST at the NRLs
The annual numbers and proportions of sputum specimens
from re-treatment TB patients received at the NRLs that had
culture contamination, positive MTB growth and successful CDST
are shown in Figure 3. There were no data for 2008.
Contamination rates each year were fairly similar in the pre-
Xpert era, but these increased in the Xpert era, particularly in
the last 2 y (Figure 3A). During the pre-Xpert era, 2.5% of
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Figure 1. Number of Xpert MTB/RIF instruments deployed each year in
Zimbabwe, 2011–2016.
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specimens had culture contamination, and this increased signiﬁ-
cantly to 10.8% in the Xpert era (p<0.001).
Positive MTB cultures each year were similar in the pre-Xpert
era and increased slightly in the Xpert era (Figure 3B). During
the pre-Xpert era, 12.9% of sputum specimens had positive MTB
cultures, which increased signiﬁcantly to 17.1% in the Xpert era
(p<0.001). The pattern of successful CDST mirrored that seen
with positive MTB cultures (Figure 3C). During the pre-Xpert era,
5.9% of sputum specimens had successful CDST, which
increased signiﬁcantly to 13.5% in the Xpert era (p<0.001).
The number and proportion of CDST results that showed any
resistance to rifampicin are shown in Figure 4. The proportions
of CDST results showing any resistance to rifampicin were fairly
similar in the pre-Xpert and Xpert eras. During the pre-Xpert era,
41% of CDST results showed any resistance to rifampicin, which
was not signiﬁcantly different to 44% in the Xpert era (p=0.61).
During the pre-Xpert era, there were also 5 (7%) CDST results
showing isoniazid monoresistance, which was not signiﬁcantly
different from 33 (4%) in the Xpert era (p=0.18).
Re-treatment TB and CDST
The number and proportion of notiﬁed re-treatment TB patients
with a successful CDST result are shown in Figure 5. In the pre-
Xpert era, less than 1% of notiﬁed re-treatment TB patients had
a successful DST. This increased in the Xpert era from 3% in
2011 to 7% in 2016.
Discussion
This is the ﬁrst study from Zimbabwe documenting the country-
wide scale-up of molecular diagnostic technology in the form of
the Xpert MTB/RIF assay and assessing how the CDST system
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Figure 2. Numbers of re-treatment TB patients who had sputum specimens received by NRLs in Zimbabwe before and during the scale-up of the
Xpert MTB/RIF assay: 2008–2016.
Table 1. Number of Xpert MTB/RIF assays performed and test results in Zimbabwe from 2012–2016
Xpert MTB/RIF assays and results Year
2012 2013 2014 2015 2016
n (%) n (%) n (%) n (%) n (%)
Number of assays each year 11 829 24 356 48 694 62 370 68 153
Successful tests 10 839 (92) 22 552 (93) 30 852 (63) 57 598 (92) 62 938 (92)
Tests showing MTB 1797 (17) 3754 (17) 2963 (10) 8739 (15) 9549 (15)
Tests showing RR-MTB 72 (4) 300 (9) 432 (15) 488 (6) 533 (6)
Tests showing errorsa 990 (8) 1804 (7) 17 842 (37) 4472 (8) 5215 (8)
aErrors include aborted assays due to probe check control failures, no results due to power failure or stoppage of the test by the operator or
invalid results.
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has functioned during this period. There were some interesting
ﬁndings.
First, there has been a remarkable scale-up of the Xpert MTB/
RIF assay in Zimbabwe and, with the exception of the year
2014, the assays performed well, with a high proportion of suc-
cessful tests and good detection rates of MTB with rifampicin
resistance generally staying below 10%. The error rates, which
in effect are wasted assays each costing about US$10, also
remained below 10%. These error rates are acceptable and simi-
lar to reports from other national programmes that have
deployed the Xpert MTB/RIF assay in the ﬁeld.20,21 In 2014 there
was a high proportion of errors, possibly due to frequent power
failures throughout the country, and these negatively impacted
the numbers and proportions of successful tests and tests
detecting MTB and RR-TB. The negative experience in 2014 was
a wake-up call leading to the National Tuberculosis Control
Programme installing backup solar-powered batteries to allow
uninterrupted power supplies to Xpert instruments. This is an
important lesson when it comes to decentralising this type of
technology to more peripheral areas with limited infrastructure.
Instrument errors may also result from poor training, inexperi-
enced users as well as defective cartridges, and it is important
to ensure that new batches of cartridges come from reliable
suppliers and are subject to quality control checks.22
Second, during the scale-up of the Xpert MTB/RIF assay, there
was indeed an increase in the number of sputum specimens
from re-treatment TB patients reaching NRLs, supporting our ini-
tial hypothesis. However, implementation of the current policy
was still far from satisfactory, with only 51% of specimens arriv-
ing at the NRLs in 2016. This is consistent with ﬁndings from a
previous study in 2014 in two Zimbabwe provinces in which the
proportion of specimens that reached the NRLs was 53%.23 We
do not know the precise reasons for this suboptimal perform-
ance, but they could include health care workers not adhering
to policy guidelines that stipulate all sputum specimens for re-
treatment TB patients be sent for CDST, a preference to just
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send specimens that are rifampicin resistant, unreliable sputum
specimen transportation systems and poor administrative sys-
tems at the NRLs. Research, especially of a qualitative nature, is
needed to ﬁnd the answers to these questions.
Third, the performance at the NRLs during the Xpert scale-up
was patchy and marginal. Levels of culture contamination
increased, especially in 2015 and 2016. At this time the labora-
tory workload was also increased by a national TB prevalence
survey and the biosafety laboratory cabinets were overdue for
service, and these factors probably negatively affected culture
processes. MTB culture rates and CDST marginally improved dur-
ing the Xpert era, which may have been due to additional tech-
nical support that was received during the prevalence survey
and the implementation of improved laboratory quality man-
agement systems. In terms of CDST results, a high proportion
showed any resistance to rifampicin, supporting our earlier
assumption that there was a preference for sending sputum
specimens from patients whose sputum specimens had RR-TB
detected on the Xpert MTB/RIF assay.
Finally, while the proportion of re-treatment TB patients who
had CDST increased in the Xpert era, the results were poor and
consistently remained below 10%.
This study has several strengths. It was a countrywide study
over 9 y using several data sources and was therefore represen-
tative of the situation in Zimbabwe with respect to specimen
referral and NRL culture processing systems. Also, the reporting
of the study was in line with Strengthening the Reporting of
Observational Studies in Epidemiology guidelines.24
However, there were some limitations. First, re-treatment TB
patients were regarded as a homogeneous group and we were
unable to stratify by region or type of re-treatment, which would
have been useful for more detailed analyses and possible policy
formulation. Second, there were data challenges. For 2008 there
were no data available for CDST in the NRLs. There were no data
about system processes such as specimens arriving at the NRL
but being rejected, time between specimen collection and
arrival at the NRL, time to get CDST results or whether the
results were sent back to referral facilities and reached the
patients. Such information requires individual rather than aggre-
gate data and should be the subject of future research. Third,
we were only able to report on the total number of Xpert tests
done each year and were unable to get disaggregated data on
how many re-treatment TB patients received this assay,
because the information was not available in the Xpert registers.
Fourth, we did not manage to collect data on the different error
codes for the Xpert MTP/RIF tests. Error codes were mainly due
to power ﬂuctuations during testing (error code 2127), poor
sample preparation (error code 2008) and excessive tempera-
tures (error code 1001). This information would have helped in
instituting targeted interventions to reduce errors and hence
wastages during Xpert MTB/RIF testing.
Despite these limitations, there are two important program-
matic implications. First, it is essential that further scale-up and
decentralisation of Xpert MTB/RIF is accompanied by reliable
and stable backup power, and this must be accompanied by
good quality control checks on cartridges, with the aim to
reduce the number of errors and therefore costs. There also
needs to be better documentation in Xpert registers about who
is receiving the assay.
Second, Zimbabwe must decide whether it wants to invest in
and try to improve the national CDST system or whether it
should disband the system, which is clearly not functioning, at
least for re-treatment TB patients. This decision must take into
account several new developments.
The use of CDST as the gold standard for RR-TB was success-
fully challenged.25 We recommend having all RR-TB patients in
Xpert tested for second-line drug resistance using LPA, in line
with new TB management guidelines. This will help in identifying
who needs an extensively drug-resistant TB regimen. There is
already new molecular diagnostic technology available, such as
the GeneXpert OMNI system (a portable, battery-operated,
single-cartridge system) and Xpert MTB/RIF Ultra (an assay with
higher sensitivity than Xpert MTB/RIF), that if used would allow
programmes to be more conﬁdent about the feasibility of
decentralization and the accuracy of diagnoses. Indeed, in 2017
the WHO recommended the use of Xpert MTB/RIF Ultra in all
settings as a replacement for Xpert MTB/RIF.26 Use of Xpert
MTB/RIF Ultra might obviate the need for conﬁrmatory CDST for
MDR-TB and RR-TB. However, there is the issue of isoniazid
monoresistance and resistance to second-line anti-TB drugs.
There is some evidence that isoniazid monoresistance (found in
5% of patients in our study and increasing in this part of Africa)
is associated with poorer treatment outcomes,27 and the WHO
recommends that high levels of isoniazid resistance warrant a
change from rifampicin–isoniazid in the continuation phase to
rifampicin–isoniazid and ethambutol.28 The WHO has also
recently recommended a new short-course regimen of 9–12
months for MDR-TB, provided patients have not been treated
with second-line drugs and/or have had resistance to ﬂuoroqui-
nolones and second-line injectable agents.29 Currently conven-
tional CDST and molecular line probe assays performed in
laboratories are the only ways of obtaining this information.
However, a new automated, cartridge-based assay has been
developed that accurately detects MTB mutations associated
with resistance to isoniazid, ﬂuoroquinolones and aminoglyco-
sides, and this holds promise as a rapid future point-of-care test
to guide therapeutic decisions for patients with TB.30 If these
new molecular technology tests become available in the ﬁeld,
the need for CDST might disappear.
In conclusion, this study documented an impressive scale-up
of the Xpert MTB/RIF assay in Zimbabwe over the last 6 y and,
apart from 1 y, the assays have performed well. During the
Xpert era there was a gradual increase in sputum specimens
from re-treatment TB patients arriving at NRLs, although per-
formance in terms of culture contamination, positive MTB cul-
tures and successful CDST results was patchy and marginal.
Zimbabwe needs to decide whether to continue supporting a
suboptimal system or invest in new molecular diagnostic
technology.
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